Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Infliximab may cause hair loss in Crohn's disease patients.

This case report describes a patient with severe alopecia totalis and atopic dermatitis who showed almost complete hair regrowth and improved skin lesions after receiving subcutaneous allergen-specific immunotherapy using house dust mites.

This study reported that the novel AKT inhibitor CCT128930 demonstrated significant antitumor activity in human cancer cell lines and xenografts, highlighting its potential as an anticancer therapy.

An arthritis drug helped a person with severe hair loss regrow their hair.

In this study, researchers found that retinoids might improve lupus nephritis resistant to conventional treatments, but the sample size was too small for significant results, and side effects were noted.

This study highlights that although mogamulizumab is highly effective for treating mycosis fungoides and Sézary syndrome, it frequently causes a variety of rashes as side effects.

This study found an increased risk of asthma and allergic rhinitis in individuals with hidradenitis suppurativa.

This article reviews current treatments for alopecia areata, discussing the potential role of JAK inhibitors and noting the need for further clinical trials, but it reports no new results.

This case report from this study demonstrates the potential of treating severe alopecia areata with a combination of microneedling, minoxidil, desoximetasone, and methylprednisolone, noting initial hair regrowth after 14 days but emphasizing the need for further research to confirm long-term efficacy and safety.

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.

In this study, tofacitinib and baricitinib showed similar effectiveness and safety in treating alopecia areata, but baricitinib had a higher rate of early responders. Baseline hair loss severity was identified as the only independent predictor of treatment response.

Tailored treatments for alopecia areata show promising results, with pulse steroids effective for mild cases and Ritlecitinib, Dupilumab, or methotrexate and prednisone effective for severe cases.

The trial helped find the best dose of deuruxolitinib for treating alopecia areata.

This study found that inhibiting the ATR kinase with VE-822 impairs DNA repair capability in quiescent human keratinocytes exposed to solar-simulated UV radiation, suggesting ATR's critical role in facilitating effective DNA damage repair and cellular recovery under UV stress conditions.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

This scoping review found that most of the 64 alopecia areata patients treated with upadacitinib in existing reports experienced significant hair regrowth, with mild side effects, but the authors call for larger studies to confirm these outcomes.

This study developed an advanced HPLC-ESI-ion trap MS(n) method for the structural identification of cyclosporin A analogs CyA and CyC and reported the first MS(n)-aided identification of a new CyA analog.

This case report describes a 38-year-old patient with trichomycosis axillaris, successfully treated with shaving, 3% erythromycin cream, and clotrimazole powder.

In this conference session, experts reviewed clinical evidence and strategies for using JAK inhibitors in managing alopecia areata, emphasizing optimal treatment practices and individual patient considerations to enhance safety and effectiveness in real-world settings.

In this experimental study, researchers found that intravitreal injections of up to 100μg of topotecan in rabbits caused no systemic or ocular toxicity, while 200μg doses resulted in localized retinal changes and decreased electroretinography amplitudes near the injection site.

This study found that applying a 1% cetirizine solution daily for 16 weeks resulted in a statistically significant increase in hair count among men with androgenetic alopecia, although improvements in global photographs were less pronounced, highlighting the need for larger studies to confirm these findings.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

PRP injections are more effective than triamcinolone for treating alopecia areata.

In this study, tofacitinib treatment in a male patient with alopecia areata led to significant hair regrowth and improvement in nail dystrophy symptoms, restoring finger function within 10 months.

This letter reports on a case of intractable ophiasis-type alopecia areata that was presumably improved by fexofenadine, but no new clinical results are presented.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This case report describes a 35-year-old man who developed an atypical DRESS syndrome after taking topiramate for migraine prevention, which resolved with drug withdrawal and symptomatic treatment.

In this study, withdrawal of baricitinib therapy in patients with severe alopecia areata who had achieved hair regrowth led to a loss of benefit in almost all patients, suggesting that continued treatment is necessary to maintain hair regrowth.

This source discusses the potential of topical JAK inhibitors, like tofacitinib, as effective treatments for autoimmune skin diseases, emphasizing their superior safety profile and minimal adverse effects compared to conventional systemic therapies.